• 110,000 contracted licences globally across 1,900+ aged care facilities
• 71,000 implemented licences with 17% increase in ARR to $3.6M
• US FDA De Novo clearance for PainChek Adult expected by Q4 2025

PainChek Ltd, the developer of the world's first smart device-based pain assessment and monitoring application, reported its quarterly activities and cashflow for the period ended 30 June 2025. Key highlights include: 110,000 contracted licences globally across over 1,900 aged care facilities, with an ARR of $5.4M once fully implemented - a 10% increase on the prior quarter. 71,000 implemented licences globally, with an ARR of $3.6M - a 17% increase on the prior year. Global customer retention remains above 85%, with a Net Retention Rate of 106%. The company completed a strongly supported A$7.5m placement in July 2025 to drive growth plans in North America and for the PainChek Infant App. PainChek has appointed a Head of Business Development for the US market, with US FDA De Novo regulatory submissions completed. Regulatory clearance is projected for late September / early October 2025 or sooner, opening up a $582m US Long Term Care market. PainChek Infant App marketing has also commenced in Australia. Cumulative PainChek pain assessments reached 12,172,000, a 103% increase over the previous year.

PainChek expects to receive US FDA De Novo regulatory clearance for the PainChek Adult app in late September / early October 2025 or sooner, opening up a $582m US Long Term Care market opportunity.

With the new A$7.5m placement, PainChek is well-positioned to drive major international expansion, including the commencement of sales in the US upon FDA clearance and the launch of the PainChek Infant App in Australia.